Wendy Colleen Moore MD

Clinical Trials

• Asthma Clinical Research Network (ACRN) Start of enrollment: 1993 Sep 01

  Withdrawn

  Phase 3

• Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) Start of enrollment: 2004 Dec 01

  Completed

  Phase 3

• Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA) Start of enrollment: 2006 Jun 01

  Completed

  Phase 3

• Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT) Start of enrollment: 2007 Jun 01

  Completed

  Phase 3

• Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) Start of enrollment: 2008 May 01

  Completed

  Phase 3

• Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma Start of enrollment: 2009 Nov 01

  Completed

  Phase 2

• Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma Start of enrollment: 2011 Apr 01

  Completed

  Phase 3

• Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment Start of enrollment: 2012 Oct 01

  Completed

  Not Applicable

• Severe Asthma Research Program

  ACTIVE_NOT_RECRUITING

• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma Start of enrollment: 2012 Oct 08

  Completed

  Phase 3

• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects Start of enrollment: 2012 Sep 28

  Completed

  Phase 3

• Severe Asthma Research Program - Wake Forest University Start of enrollment: 2012 Dec 01

  Completed

• Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Start of enrollment: 2013 Sep 19

  Completed

  Phase 3

• Best African American Response to Asthma Drugs Start of enrollment: 2014 Feb 01

  Completed

  Phase 3

• Study of COPD Subgroups and Biomarkers

  ACTIVE_NOT_RECRUITING

• Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy Start of enrollment: 2014 Apr 28

  Completed

  Phase 3

• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) Start of enrollment: 2014 Aug 05

  Completed

  Phase 3

• Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma Start of enrollment: 2016 Jan 27

  Completed

  Phase 2

• Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) Start of enrollment: 2017 Jul 17

  COMPLETED

  PHASE2

• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Start of enrollment: 2018 Feb 27

  COMPLETED

• Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Start of enrollment: 2018 Aug 01

  Completed

  Phase 3

• A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma Start of enrollment: 2018 Aug 29

  COMPLETED

  PHASE3

• GB001 in Adult Subjects With Moderate to Severe Asthma Start of enrollment: 2018 Oct 22

  Completed

  Phase 2

• Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma Start of enrollment: 2019 Jan 25

  Completed

  Phase 3

• Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Start of enrollment: 2019 Oct 17

  RECRUITING

  PHASE4

• PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study Start of enrollment: 2019 Dec 19

  ACTIVE_NOT_RECRUITING

  PHASE2

• American Lung Association (ALA) Lung Health Cohort Start of enrollment: 2021 Oct 29

  RECRUITING

• SPIROMICS Study of Early COPD Progression (SOURCE) Start of enrollment: 2021 Sep 08

  RECRUITING

• A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma Start of enrollment: 2024 May 31

  RECRUITING

  PHASE3

• Deep Functional Phenotyping of the ALA Lung Health Cohort Start of enrollment: 2024 Feb 12

  RECRUITING

• A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma Start of enrollment: 2017 Dec 11

  Unknown status

• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Start of enrollment: 2021 Jan 26

  ACTIVE_NOT_RECRUITING

  PHASE3

• Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma Start of enrollment: 2019 Jun 14

  COMPLETED

  PHASE3

• Join now to see all